Clinical Trial Update: Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing BeGEV (Bendamustine, Gemcitabine, and Vinorelbine) as induction therapy for relapsed/refractory Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Treanda) (bendamustine)
• Gemcitabine (Gemzar) (gemcitabine)
• Vinorelbine (Navelbine) (vinorelbine tartrate)

Snippet

Sponsor: Armando Santoro, MD | Conditions: Hodgkin's Lymphoma | Phase 2 | Status: UNKNOWN